Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT07082192Phase 3Recruiting
- Sponsor
- Zhimeng Biopharma
- Start
- Oct 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of CB03-154 in amyotrophic lateral sclerosis (ALS), sponsored by Zhimeng Biopharma. Started Oct 2025; status: recruiting.
02
Drugs
CB03-154
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07082192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07082192.